Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEK and the inhibitors: from bench to bedside

12 Apr 2013

Abstract excerpt

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23587417
DOI: 10.1186/1756-8722-6-27

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEK and the inhibitors: from bench to bedsidePMID 23587417Read ↗

The clinical development of MEK inhibitorsSemantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

[BRAF inhibitor and MEK inhibitor].Semantic proximity Read ↗

Targeting MEK in non-small cell lung cancer.Semantic proximity Read ↗

Novel mitogen-activated protein kinase kinase inhibitors.Semantic proximity Read ↗

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read ↗

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.Semantic proximity Read ↗

Clinical experience of MEK inhibitors in cancer therapy.Semantic proximity Read ↗

Oncogenic signaling of MEK5-ERK5.Semantic proximity Read ↗

Clinical Development of BRAF plus MEK Inhibitor Combinations.Semantic proximity Read ↗

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.Semantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.